Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 1, 2023American Society of Clinical Oncology Educational Book

Management Considerations for Patients With Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

CDCassandra DuarteUniversity of Colorado Cancer CenterMKManali KamdarUniversity of Colorado Cancer Center

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Duarte et al. (2023) studied this question.

synapsesocial.com/papers/69decc2040ea06567955994chttps://doi.org/10.1200/edbk_390802
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Relapse Is Uncommon in Patients with Large B-Cell Lymphoma Who Are in Complete Remission at the End of Fixed-Course Glofitamab Treatment2022 · 20 citations
  2. 2Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma1995 · 2,458 citations
  3. 3Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma2019 · 785 citations
  4. 4Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation2021 · 47 citations
  5. 5Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma2021 · 142 citations